Breaking World Pharma News

COVID-19 drug lead treatments identified

An international team of researchers has tested more than 10,000 compounds to identify six drug candidates that may help treat COVID-19.

The research, involving University of Queensland scientist Professor Luke Guddat, tested the efficacy of approved drugs, drug candidates in clinical trials and other compounds.

GSK and Vir Biotechnology enter collaboration to find coronavirus solutions

GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) announced they have signed a binding agreement to enter into a collaboration to research and develop solutions for coronaviruses, including SARS-CoV-2, the virus that causes COVID-19.

Potential harms of chloroquine, hydroxychloroquine and azithromycin for treating COVID-19

Chloroquine, hydroxychloroquine and azithromycin are being used to treat and prevent COVID-19 despite weak evidence for effectiveness, and physicians and patients should be aware of the drugs' potentially serious adverse events, states a review in CMAJ (Canadian Medical Association Journal).

Novartis announces plan to initiate clinical study of Jakavi® in severe COVID-19 patients and establish international compassionate use program

Novartis announced plans to initiate a Phase III clinical trial in collaboration with Incyte to evaluate the use of Jakavi® (ruxolitinib) for treatment of a type of severe immune overreaction called cytokine storm that can lead to life-threatening respiratory complications in patients with COVID-19.

Johnson & Johnson announces a lead vaccine candidate for COVID-19

Johnson & Johnson (NYSE: JNJ) (the Company) announced the selection of a lead COVID-19 vaccine candidate from constructs it has been working on since January 2020; the significant expansion of the existing partnership between the Janssen Pharmaceutical Companies of Johnson & Johnson and the Biomedical Advanced Research and Development Authority (BARDA);

Lancaster academic sees positives in first published clinical trial of COVID-19 treatment

A Lancaster University statistician who worked on the first published large randomised clinical trial for a potential treatment for the COVID-19 virus said the scientific community was coming together to combat the coronavirus. There are currently no specific treatments for COVID-19. However, it is possible that some existing drugs, usually used for other conditions, may have some benefits.

Trial drug can significantly block early stages of COVID-19 in engineered human tissues

An international team led by University of British Columbia researcher Dr. Josef Penninger has found a trial drug that effectively blocks the cellular door SARS-CoV-2 uses to infect its hosts. The findings, published in Cell, hold promise as a treatment capable of stopping early infection of the novel coronavirus.

Possible coronavirus drug identified by Australian scientists

A collaborative study led by Monash University's Biomedicine Discovery Institute (BDI) in Melbourne, Australia, with the Peter Doherty Institute of Infection and Immunity (Doherty Institute), has shown that an anti-parasitic drug already available around the world kills the virus within 48 hours.

FDA Coordinates National Effort to Develop Blood-Related Therapies for COVID-19

The U.S. Food and Drug Administration continues to play a critical role in accelerating medical countermeasures to treat and prevent COVID-19. As part of the response to this pandemic, the agency is taking the lead on a national effort to facilitate the development of, and access to, two investigational therapies derived from human blood.

Clues to COVID-19 coronavirus's vulnerability emerge from an antibody against SARS

An antibody recovered from a survivor of the SARS epidemic in the early 2000s has revealed a potential vulnerability of the new coronavirus at the root of COVID-19, according to a study from scientists at Scripps Research.

The study, published today in Science, is the first to map a human antibody's interaction with the new coronavirus at near-atomic-scale resolution.

WORLDPHARMANEWS

Breaking World Pharma News

COVID-19 drug lead treatments identified

GSK and Vir Biotechnology enter collaboration to find coronavirus solutions

Potential harms of chloroquine, hydroxychloroquine and azithromycin for treating COVID-19

Novartis announces plan to initiate clinical study of Jakavi® in severe COVID-19 patients and establish international compassionate use program

Johnson & Johnson announces a lead vaccine candidate for COVID-19

Lancaster academic sees positives in first published clinical trial of COVID-19 treatment

Trial drug can significantly block early stages of COVID-19 in engineered human tissues

Possible coronavirus drug identified by Australian scientists

FDA Coordinates National Effort to Develop Blood-Related Therapies for COVID-19

Clues to COVID-19 coronavirus's vulnerability emerge from an antibody against SARS

More Pharma News ...

Business & Industry

Research & Development

Conferences & Events

Regulatory Affairs